BWXT Medical and Bayer AG Enter into Agreement for the Development and Production of Actinium-225
(OTTAWA, Ontario – September 16, 2021) – BWX Technologies, Inc. (NYSE: BWXT) announced today that its BWXT Medical Ltd. subsidiary (BWXT Medical) has entered into an agreement with Bayer AG (Bayer) to develop Actinium-225 (Ac-225) supply and further partnering opportunities on finished products as both companies broaden their respective commercialization strategies for targeted radionuclide therapies (TRTs) and other innovative products.
BWXT Medical Enters into a New Long-Term Agreement with Boston Scientific
(Ottawa, Ontario – May 10, 2021) – BWXT Medical Ltd. (BWXT Medical) announced today that it has entered into a new long-term, mutually exclusive agreement to manufacture TheraSphere™ Y-90 Glass Microspheres for Boston Scientific, a leading global medical device company.
BWXT Names Nuclear Medicine Business as BWXT Medical
(LYNCHBURG, Va. – Feb. 1, 2021) – BWX Technologies, Inc. (NYSE: BWXT) today announced that its subsidiary BWXT ITG Canada, Inc., a nuclear medicine company, has been renamed BWXT Medical Ltd. (BWXT Medical), in order to better align with the company’s products, customer base and strategy.
OPG and BWXT Make Significant Progress in Production of Life-Saving Medical Isotope at Darlington Nuclear Generating Station
Darlington to become first large-scale nuclear station to produce molybdenum-99.
BWXT Appoints Martyn Coombs to lead Nuclear Medicine Business as President, BWXT ITG Canada
(LYNCHBURG, Va. – July 6, 2020) – BWX Technologies, Inc. (NYSE: BWXT) today announced that Martyn Coombs has been appointed president, BWXT ITG Canada, Inc. (BWXT ITG Canada), effective July 20, 2020. In this role, Coombs will have P&L responsibility for BWXT’s medical isotope business, based in Canada, with facilities in Kanata, Ontario and Vancouver, British Columbia. In addition to leading the existing business, Coombs will also be responsible for guiding the successful launch of BWXT’s technetium-99m generator product line currently in development, and growing the overall business. Coombs will be replacing Tom Burnett, who is retiring.